cafedrine
Sign in to saveCafedrine (, ), sold under the brand name Akrinor among others, is a chemical linkage of norephedrine and theophylline and is a cardiac stimulant and antihypotensive agent used to increase blood pressure in people with hypotension. It has been marketed in Europe, South Africa, and Indonesia.
Research
53 papers- Cafedrine/Theodrenaline (20:1) Is an Established Alternative for the Management of Arterial Hypotension in Germany-a Review Based on a Systematic Literature Search.Frontiers in pharmacology · 2017
- Cafedrine/theodrenaline in anaesthesia: influencing factors in restoring arterial blood pressure.Der Anaesthesist · 2015
- Phenylephrine versus cafedrine/theodrenaline (Akrinor) for the treatment of spinal anaesthesia-induced maternal hypotension during caesarean section: a retrospective single-centre cohort study.BMJ open · 2022
- [Drug interaction between ceftriaxone and theodrenaline/cafedrine : A case example].Die Anaesthesiologie · 2023
- A fixed 20:1 combination of cafedrine/theodrenaline increases cytosolic Ca(2+) concentration in human tracheal epithelial cells via ryanodine receptor-mediated Ca(2+) release.Scientific reports · 2023
via PubMed
Wikidata facts
- Mass
- 357.18
Show 5 more facts
- isomeric SMILES
- C[C@@H]([C@@H](C1=CC=CC=C1)O)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C
- chemical formula
- C₁₈H₂₃N₅O₃
- canonical SMILES
- CC(C(C1=CC=CC=C1)O)NCCN2C=NC3=C2C(=O)N(C(=O)N3C)C
- subject has role
- vasodilator agent
- Commons category
- Cafedrine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Cafedrine (, ), sold under the brand name Akrinor among others, is a chemical linkage of norephedrine and theophylline and is a cardiac stimulant and antihypotensive agent used to increase blood pressure in people with hypotension. It has been marketed in Europe, South Africa, and Indonesia.
There has been concern about cafedrine as a potential performance-enhancing drug and doping agent in sports.
Excerpted from Wikipedia’s “cafedrine” article, available under the CC BY-SA 4.0 licence.